AR107800A1 - Proceso para la preparación de un conjugado de anticuerpo-rifamicina - Google Patents

Proceso para la preparación de un conjugado de anticuerpo-rifamicina

Info

Publication number
AR107800A1
AR107800A1 ARP170100538A ARP170100538A AR107800A1 AR 107800 A1 AR107800 A1 AR 107800A1 AR P170100538 A ARP170100538 A AR P170100538A AR P170100538 A ARP170100538 A AR P170100538A AR 107800 A1 AR107800 A1 AR 107800A1
Authority
AR
Argentina
Prior art keywords
formula
preparation
otf
compound
reacting
Prior art date
Application number
ARP170100538A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR107800A1 publication Critical patent/AR107800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/78—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen procesos para la preparación de F-benzoxazinorifamicina y compuestos intermedios para la conjugación con un anticuerpo. Reivindicación 1: Un proceso para la preparación de F-benzoxazinorifamicina de fórmula (1), que comprende hacer reaccionar rifamicina S de fórmula (2), 2-amino-5-fluorobenceno-1,3-diol de fórmula (3), y uno o más oxidantes seleccionados entre TEMPO y los análogos de TEMPO, aire ambiente, oxígeno gaseoso, benzoquinona, óxido de manganeso (MnO₂), (PhI(OTs)OH, peryodato de sodio (NalO₄), cloranilo, peróxido de hidrógeno, Fe₂O₃, Na₂S₂O₈, Co(acac)₃, Mn(acac)₂, Cu(OAc)₂, CuO, CuBr₂, ZnCl₂, InCl₃, Ag(OTf)₂, Sc(OTf)₃, e Yb(OTf)₃, para formar el compuesto de fórmula (1). Reivindicación 18: Un proceso para la preparación de 2-amino-5-fluorobenceno-1,3-diol de fórmula (3), que comprende: (a) hacer reaccionar 1,3,5-trifluoro-2-nitrobenceno de fórmula (4), fenilmetanol, y un reactivo básico seleccionado entre bis(trimetilsililamida)diisopropilamida de litio, y un reactivo alcóxido, para formar (((5-fluoro-2-nitro-1,3- fenilen)bis(oxi))bis(metilen))dibenceno de fórmula (5); y (b) hacer reaccionar el compuesto de fórmula (5) con hidrógeno gaseoso y un catalizador metal heterogéneo para formar el compuesto de fórmula (3).
ARP170100538A 2016-03-04 2017-03-03 Proceso para la preparación de un conjugado de anticuerpo-rifamicina AR107800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662303556P 2016-03-04 2016-03-04

Publications (1)

Publication Number Publication Date
AR107800A1 true AR107800A1 (es) 2018-06-06

Family

ID=58361102

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100538A AR107800A1 (es) 2016-03-04 2017-03-03 Proceso para la preparación de un conjugado de anticuerpo-rifamicina

Country Status (13)

Country Link
US (2) US10336683B2 (es)
EP (1) EP3423457B1 (es)
JP (2) JP6705904B2 (es)
KR (1) KR102204805B1 (es)
CN (1) CN108713020A (es)
AR (1) AR107800A1 (es)
AU (1) AU2017228468B2 (es)
BR (1) BR112018014355A2 (es)
CA (1) CA3012046C (es)
IL (1) IL260465B (es)
MX (1) MX2018010491A (es)
SG (1) SG11201807537RA (es)
WO (1) WO2017152083A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012046C (en) 2016-03-04 2020-11-10 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
CN108047250B (zh) * 2018-02-12 2020-08-14 丹诺医药(苏州）有限公司 一种利福霉素-硝基咪唑偶联分子的应用
CN110687217B (zh) * 2018-08-07 2021-04-23 中国科学院大连化学物理研究所 液相色谱测定利福霉素s的方法
CN110687218B (zh) * 2018-08-07 2021-04-23 中国科学院大连化学物理研究所 液相色谱测定苯并噁嗪利福霉素的方法
EP3897841A1 (en) * 2018-12-21 2021-10-27 Regeneron Pharmaceuticals, Inc. Rifamycin analogs and antibody-drug conjugates thereof
EP4387618A1 (en) * 2021-08-20 2024-06-26 Rutgers, the State University of New Jersey Dual-targeted rna polymerase inhibitors: conjugates of benzoxazino- and spiro-rifamycins with n?-aroyl- n-aryl-phenylalaninamides
CN114436864A (zh) * 2022-02-17 2022-05-06 浙江鼎龙科技股份有限公司 一种2-甲基-5氨基苯酚的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877732A (en) 1958-08-12 1961-09-20 Lepetit Spa The antibiotic rifomycin, its components and methods of preparing same
US4690919A (en) 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS63183587A (ja) 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノリフアマイシン誘導体
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
MXPA06002088A (es) 2003-08-22 2006-08-11 Activbiotics Inc Analogos de rifamicina y usos de los mismos.
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP1701962A4 (en) 2003-12-23 2008-03-05 Activbiotics Inc RIFAMYCIN ANALOGS AND USES THEREOF
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
CN101395259A (zh) 2005-12-14 2009-03-25 活跃生物药物学有限公司 利福霉素类似物及其应用
US7678791B2 (en) 2006-07-12 2010-03-16 Cumbre Ip Ventures, L.P. Nitroheteroaryl-containing rifamycin derivatives
DK2121920T3 (da) 2007-03-01 2011-11-21 Symphogen As Fremgangsmåde til kloning af sammenhørende antistoffer
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
RU2505544C2 (ru) 2007-10-19 2014-01-27 Дженентек, Инк. Антитела против tenb2, сконструированные с цистеином, и конъюгаты антитело - лекарственное средство
WO2009064792A1 (en) 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Quinolone carboxylic acid-substituted rifamycin derivatives
EP2234954B1 (en) * 2007-12-20 2015-02-18 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2324041A4 (en) 2008-08-13 2012-06-13 Targanta Therapeutics Corp PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20150147328A1 (en) 2012-05-07 2015-05-28 Mogam Biotechnology Institute Vaccine composition for preventing staphyllococcus aureus infection
JP6371758B2 (ja) 2013-03-12 2018-08-08 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
US20140356375A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
PT3004162T (pt) 2013-05-31 2020-05-27 Genentech Inc Anticorpos e conjugados anti-parede teicoica
US9884126B2 (en) 2013-05-31 2018-02-06 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
EP3226908A1 (en) * 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
EP3226911A1 (en) * 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
CA3012046C (en) 2016-03-04 2020-11-10 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate

Also Published As

Publication number Publication date
JP6705904B2 (ja) 2020-06-03
KR20180118173A (ko) 2018-10-30
IL260465B (en) 2020-11-30
EP3423457B1 (en) 2021-02-17
SG11201807537RA (en) 2018-09-27
KR102204805B1 (ko) 2021-01-20
US20170252457A1 (en) 2017-09-07
AU2017228468A1 (en) 2018-07-26
BR112018014355A2 (pt) 2018-12-18
US10689325B2 (en) 2020-06-23
JP2019510740A (ja) 2019-04-18
EP3423457A1 (en) 2019-01-09
CA3012046C (en) 2020-11-10
CN108713020A (zh) 2018-10-26
AU2017228468B2 (en) 2019-12-05
JP2020090506A (ja) 2020-06-11
WO2017152083A1 (en) 2017-09-08
US10336683B2 (en) 2019-07-02
US20190270695A1 (en) 2019-09-05
MX2018010491A (es) 2018-11-09
CA3012046A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
AR107800A1 (es) Proceso para la preparación de un conjugado de anticuerpo-rifamicina
Voutyritsa et al. Organocatalytic oxidation of substituted anilines to azoxybenzenes and nitro compounds: mechanistic studies excluding the involvement of a dioxirane intermediate
Besnard et al. On the spontaneous carboxylation of 1-butyl-3-methylimidazolium acetate by carbon dioxide
CO6430455A2 (es) Proceso para la producción de compuestos de ácido quetomalónico o sus hidratos
FI3587400T3 (fi) Menetelmä pde4:n estäjän valmistamiseksi
AR073865A1 (es) Un metodo para producir sulfuro de litio.
GB1484513A (en) Polyphenylene ether copolymers
AR092001A1 (es) Proceso para la prodccion de compuestos quimicos a partir de dioxido de carbono
RU2014152878A (ru) Катализатор для получения высших спиртов
Wang et al. Synthesis of cyclic carbonates from CO 2 and epoxides catalyzed by low loadings of benzyl bromide/DMF at ambient pressure
ES2055824T3 (es) Emulsionantes y un procedimiento para la obtencion de dispersiones polimeras homodispersas y gruesamente divididas con empleo de estos emulsionantes.
WO2015082422A3 (en) Process for reacting chemical compounds
KR20170094118A (ko) 카르복실산 에스테르의 제조 방법
CO2018007613A2 (es) Sistema de depuración de dióxido de azufre y proceso para la producción de productos de potasio
IN2014DN07290A (es)
CL2018003057A1 (es) Uso de una composición de sal de nitrato como un medio de transferencia de calor o almacenamiento de calor para la primera operación de un aparato que contiene estos medios.
Mamone et al. Reactivity of carbon dioxide in hydrofluoroethers: a facile access to cyclic carbonates
Luo et al. Oxidation of alcohols to carbonyl compounds with molecular iodine in the presence of potassium tert-butoxide
Uchida et al. Gas-phase ozone reactions with Z-3-hexenal and Z-3-hexen-1-ol: Formation yields of OH radical, propanal, and ethane
Chowdhury et al. Manganese (III)-Based Oxidative Radical Cyclization of Terminal Alkadienes with N, N'-Bis (3-oxobutanoyl)-α, ω-alkanediamines. Formation of Macrodiamides
Dossmann et al. Formation and Characterization of Gaseous Adducts of Carbon Dioxide to Magnesium,(CO2) MgX−(X= OH, Cl, Br)
RU2012143346A (ru) Способ получения трис (перфторалкил) фосфиноксиды
US9586926B2 (en) Methods of making alkylene carbonates and methods of converting CO2
WO2008083635B1 (en) A method for the preparation of montelukast
Antoniotti et al. Facile preparation of metallic triflates and triflimidates by oxidative dissolution of metal powders

Legal Events

Date Code Title Description
FB Suspension of granting procedure